Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,187
Out of 5,106 analysts
39
Total ratings
24.49%
Success rate
-35.11%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $22.99 | +147.93% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.66 | +1,567.17% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.33 | +152.10% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.13 | +523,793.81% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.11 | +1,521.62% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $2.28 | +31,215.79% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.37 | +5,236.18% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $4.98 | +19,980.32% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.62 | +23,104.42% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $12.55 | +186.85% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $3.37 | +534,024.63% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $10.37 | +189.30% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.77 | +2,854.21% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $7.07 | +98.02% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $1.05 | +2,057,042.86% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.36 | +488.24% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.15 | +4,551.16% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.81 | +49,142.89% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $8.85 | +329.38% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.06 | +4,560.19% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.01 | +546.77% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $22.99
Upside: +147.93%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.66
Upside: +1,567.17%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.33
Upside: +152.10%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.13
Upside: +523,793.81%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.11
Upside: +1,521.62%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $2.28
Upside: +31,215.79%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.37
Upside: +5,236.18%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $4.98
Upside: +19,980.32%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.62
Upside: +23,104.42%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $12.55
Upside: +186.85%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $3.37
Upside: +534,024.63%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $10.37
Upside: +189.30%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.77
Upside: +2,854.21%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $7.07
Upside: +98.02%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $1.05
Upside: +2,057,042.86%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.36
Upside: +488.24%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.15
Upside: +4,551.16%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.81
Upside: +49,142.89%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $8.85
Upside: +329.38%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.06
Upside: +4,560.19%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.01
Upside: +546.77%